Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alkermes (ALKS)
NASDAQ:ALKS
Holding ALKS?
Track your performance easily
ALKS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.01 - $32.88
Previous Close$28.45
Volume1.07M
Average Volume (3M)1.86M
Market Cap
$4.67B
Enterprise Value$4.29B
Total Cash (Recent Filing)$745.05M
Total Debt (Recent Filing)$370.11M
Price to Earnings (P/E)16.9
Beta0.40
Next Earnings
Oct 23, 2024EPS Estimate
$0.73Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)1.69
Shares Outstanding164,668,329
10 Day Avg. Volume1,164,737
30 Day Avg. Volume1,863,218
Standard Deviation0.10
R-Squared0.05
Alpha0.00322
Financial Highlights & Ratios
Price to Book (P/B)3.99
Price to Sales (P/S)2.70
Price to Cash Flow (P/CF)55.30
P/FCF Ratio66.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit3.04
Enterprise Value/Ebitda7.11
Forecast
1Y Price Target
$36.38Price Target Upside27.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Alkermes News
PremiumPre-Earnings
Is ALKS a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAlkermes is advancing ALKS-2680 in Phase 2 trials for narcolepsy, representing a significant potential opportunity.
Sales PerformanceLybalvi's sales in 2Q saw revenues up 52% and total prescriptions up 44% year-over-year, driven by greater depth within existing prescribers and new prescriptions.
Stock BuybackAlkermes repurchased approximately $3.5 million shares for $85 million, enhancing the EPS growth profile.
Bears Say
Clinical DevelopmentRisks include challenges in clinical development, regulatory approval, and commercial execution.
EarningsManagement expects a decrease of around $20 million in royalties due to the loss of Invega Sustenna royalties.
Market DemandManagement anticipates a slowdown in the third quarter due to typical summer demand patterns.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ALKS FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was $22.01 and its highest was $32.88 in the past 12 months.
What is Alkermes’s market cap?
Currently, no data Available
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Oct 23, 2024 which is in 52 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Jul 24, 2024. The company reported $0.7 earnings per share for the quarter, missing the consensus estimate of $0.704 by -$0.004.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes pays a Notavailable dividend of $1.64 which represents an annual dividend yield of N/A. See more information on Alkermes dividends here
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is $0.73.
How many shares outstanding does Alkermes have?
Alkermes has 164,668,330 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of $0.7 in its last earnings report, missing expectations of $0.704. Following the earnings report the stock price went up 6.04%.
Which hedge fund is a major shareholder of Alkermes?
Among the largest hedge funds holding Alkermes’s share is Baker Bros Advisors LP. It holds Alkermes’s shares valued at 101M.
---
Alkermes Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.38 (27.87% Upside)
$36.38 (27.87% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.13%
12-Months-Change
Fundamentals
Return on Equity
26.67%
Trailing 12-Months
Asset Growth
0.90%
Trailing 12-Months
Company Description
Alkermes
Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
---
ALKS Company Deck
---
ALKS Earnings Call
Q2 2024
0:00 / 0:00
---
ALKS Revenue Breakdown
55.31% Product sales, net
44.69% Manufacturing and royalty revenues
<0.01% Research and development revenue
0.00% License revenue
---
ALKS Stock 12 Month Forecast
Average Price Target
$36.38
▲(27.87% Upside)
Technical Analysis
Best Analysts Covering ALKS
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+6.61%
reiterated a buy rating last month
Copying Uy Ear's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +6.61% per trade.
---